| Generic (Common) Name | Brand Name | Company | Year Approved |
| Protease Inhibitors (PIs) | |||
| amprenavir | Agenerase | GlaxoSmithKline | 1999; withdrawn 2007 |
| atazanavir | Reyataz | Bristol-Myers Squibb | 2003 |
| darunavir | Prezista | Tibotec | 2006 |
| fosamprenavir | Lexiva (U.S.) Telzir (Europe) | ViiV Healthcare | 2003 |
| indinavir | Crixivan | Merck | 1996 |
| lopinavir/ritonavir | Kaletra | Abbott | 2000; Meltrex formulation 2005 |
| nelfinavir | Viracept | ViiV Healthcare | 1997 |
| ritonavir | Norvir | Abbott | 1996 |
| saquinavir | Invirase (hard gel) Fortovase (soft gel) | Roche | 1995 1997; withdrawn 2005 |
| tipranavir | Aptivus | Boehringer Ingelheim | 2005 |
| Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) | |||
| abacavir | Ziagen | ViiV Healthcare | 1998 |
| didanosine (ddI) | Videx | Bristol-Myers Squibb | 1989; Videx EC 2000 |
| emtricitabine (FTC) | Emtriva | Gilead | 2003 |
| lamivudine (3TC) | Epivir | ViiV Healthcare | 1995 |
| stavudine (d4T) | Zerit | Bristol-Myers Squibb | 1994 |
| tenofovir DF | Viread | Gilead | 2002 |
| zalcitabine (ddC) | Hivid | Roche | 1992; withdrawn 2005 |
| zidovudine (AZT) | Retrovir | ViiV Healthcare | 1987 |
| Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) | |||
| delavirdine | Rescriptor | ViiV Healthcare | 1997 |
| efavirenz | Sustiva (U.S.) Stocrin (elsewhere) | Bristol-Myers Squibb | 1998 |
| etravirine | Intelence | Tibotec | 2008 |
| nevirapine | Viramune | Boehringer Ingelheim | 1996 |
| Other Classes | |||
| enfuvirtide (T-20; fusion inhibitor) | Fuzeon | Roche/Trimeris | 2003 |
| maraviroc (CCR5 antagonist) | Selzentry (U.S.) Celsentri (elsewhere) | ViiV Healthcare | 2007 |
| raltegravir (integrase inhibitor) | Isentress | Merck | 2007 |
| Fixed-Dose Combinations | |||
| lamivudine/abacavir (NRTI) | Epzicom (U.S.) Kivexa (Europe) | ViiV Healthcare | 2004 |
| tenofovir/emtricitabine (NRTI) | Truvada | Gilead | 2004 |
| tenofovir/emtricitabine/efavirenz (NRTI/NNRTI) | Atripla | Gilead/Bristol-Myers Squibb | 2006 |
| zidovudine/lamivudine (NRTI) | Combivir | ViiV Healthcare | 1997 |
| zidovudine/lamivudine/abacavir (NRTI) | Trizivir | ViiV Healthcare | 2000 |
This article was originally published January 1, 2010 and most recently updated March 1, 2010.
© 2025 HealthCentral LLC. All rights reserved.
More Like This
PrEP (HIV Pre-Exposure Prophylaxis)
Drug Guide: Cabotegravir for HIV PrEP
Antiretroviral Therapy
Long-Acting Injectable ART Effective in People With High BMI
Antiretroviral Therapy
Injectable LA-ART Satisfaction Is High in Urban U.S. HIV Clinic
Antiretroviral Therapy
Long-Acting ART Update: Viral Rebound Risk; Pediatric Use; Subcutaneous Dosing
